Concern about high out-of-pocket spending for insulin has prompted states, payers, and pharmacy benefit managers to limit cost-sharing in the US.1,2 In addition to insulin, patients with type 1 diabetes might have out-of-pocket expenses for other care, such as diabetes-related supplies. The gene discussed is INS; the disease is type 1 diabetes mellitus.